Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/21125
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.date.accessioned | 2021-07-06T10:17:39Z | - |
dc.date.available | 2021-07-06T10:17:39Z | - |
dc.date.issued | 2005-08 | - |
dc.identifier.citation | Ali, R. vd. (2005). "Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission", Leukemia Research, 29(8), 971-973. | en_US |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.uri | https://doi.org/10.1016/j.leukres.2005.01.009 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0145212605000536 | - |
dc.identifier.uri | http://hdl.handle.net/11452/21125 | - |
dc.description.abstract | Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatimb and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation. (c) 2005 Elsevier Ltd. All rights reserved. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Pergamon-Elsevier Science | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Chronic myelogenous leukemia | en_US |
dc.subject | Pregnancy | en_US |
dc.subject | Imatinib | en_US |
dc.subject | Management | en_US |
dc.subject | Oncology | en_US |
dc.subject | Hematology | en_US |
dc.title | Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000230369800015 | tr_TR |
dc.identifier.scopus | 2-s2.0-20544435207 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 971 | tr_TR |
dc.identifier.endpage | 973 | tr_TR |
dc.identifier.volume | 29 | tr_TR |
dc.identifier.issue | 8 | tr_TR |
dc.relation.journal | Leukemia Research | en_US |
dc.contributor.buuauthor | Ali, Rıdvan | - |
dc.contributor.buuauthor | Özkalemkaş, Fahir | - |
dc.contributor.buuauthor | Özçelik, Tülay | - |
dc.contributor.buuauthor | Özkocaman, Vildan | - |
dc.contributor.buuauthor | Ozan, Ülkü | - |
dc.contributor.buuauthor | Kimya, Yalçın | - |
dc.contributor.buuauthor | Köksal, Nilgün | - |
dc.contributor.buuauthor | Gülten, Tuna | - |
dc.contributor.buuauthor | Yakut, Tahsin | - |
dc.contributor.buuauthor | Tunalı, Ahmet | - |
dc.contributor.researcherid | AAH-1854-2021 | tr_TR |
dc.contributor.researcherid | AAG-8495-2021 | tr_TR |
dc.identifier.pubmed | 15978950 | tr_TR |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Hematology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q2 | en_US |
Koleksiyonlarda Görünür: | Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.